Status:
UNKNOWN
15% TOPICAL RESORCINOL FOR HURLEY I-II HIDRADENITIS SUPPURATIVA.
Lead Sponsor:
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Conditions:
HYDRADENITIS
Eligibility:
All Genders
18+ years
Brief Summary
Prospective, observational cross-sectional study to evaluate the response of patients with HS I-II to monotherapy treatment of topical resorcin 15%, taking into account its safety, impact on quality o...
Eligibility Criteria
Inclusion
- Age \> 18 years.
- Diagnosed with HS Hurley I-II degree.
- Patients that have at least 1 or more swollen up nodules and/or abscess.
- Availability of affected region control ultrasound prior to resorcine treatment beginning.
Exclusion
- Age \< 18 years.
- Number of draining fistula above 20.
- Patients in active treatment with immunomodulators.
- Patients in active treatment with antibiotics.
Key Trial Info
Start Date :
May 15 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 30 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04099212
Start Date
May 15 2019
End Date
August 30 2020
Last Update
February 12 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitario Virgen Macarena
Seville, Spain, 41009